Positron Corporation that the Company has entered into a strategic business relationship with Neusoft Medical Systems for manufacturing, distribution, and continued R&D advancements of Positron's new PET/CT nuclear imaging device. Positron, in collaboration with Neusoft, will submit a new device 510K application with the FDA for the certification of Positron's PET/CT nuclear imaging system. Positron's PET/CT system is based on the current NeuWise PET/CT system.

The scope of the Positron/Neusoft agreement is to further develop the utilization of its PET/CT technology and services for nuclear cardiology while expanding into the field of oncology imaging diagnostics and clinical services. The U.S. is the largest total addressable market for both cardiology and oncology fields and will continue to be Positron's primary focus, however expansion into Canada and Mexico are parts of the Company's future which are both sizable opportunities. As part of the Positron/Neusoft agreement, the Company has ordered its new PET/CT system for validation testing with one or more nuclear cardiologist that are champions in this area of expertise.

This validation will be in parallel with an FDA submission set to begin in the second quarter of 2022. The Company has also purchased all current Attrius PET system inventory and components and anticipates installations of multiple systems with new customers in 2022.